Health Care & Life Sciences » Pharmaceuticals | Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.82
Market Cap
$2.54 M
Shares Outstanding
36.35 M
Public Float
35.19 M

Profile

Address
550 Sylvan Avenue
Englewood Cliffs New Jersey 07632
United States
Employees -
Website http://www.immunepharma.com
Updated 09/14/2018
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases.

Financials

View All
Created with Highcharts 5.0.14Immune Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.5 7605 76024 16624 16617 15717 15732 66132 66117 88917 88920132014201520162017010k20k30k40k
Created with Highcharts 5.0.14Immune Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.1919220000002013201420152016201705101520

Anthony S. Fiorino
CEO, COO, Chief Medical Officer & Director
Daniel Kazado
Director